Please assess the completion status of the following clinical trial:

Trial Title: Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old.~* Confirmed HIV-1 uninfected.~* Willing to provide screening informed consent~* Currently pregnant~* Considered high risk for HIV infection~  * Unprotected sex during pregnancy~ * HIV status of current sexual partner is positive or unknown~* Results of Hepatitis B Virus (HBV) screening (HBsAg testing) available from specimen obtained within 30 days prior to entry~* Plans to deliver in the study affiliated hospital~* Has no plans to move residence outside of the catchment area during the 18 months following delivery~Exclusion Criteria:~* HIV infected~* \<18 years of age~* The following laboratory values from a specimen obtained within 30 days prior to study entry:~  * Hemoglobin \<9.5 g/dL~ * White Blood Cell Count (WBC) \< 1500 cells/mm3~ * Absolute Neutrophil Count (ANC) \< 750 cells/mm3~ * Platelets \< 100,000 cells/mm3~ * Alanine Aminotransferase (ALT) \> 2.5 x upper limit of normal (ULN)~ * Estimated creatinine clearance of \< 70 ml/min using the cockcroft-gault equation for women: {(\[140 - age (years)\] x \[weight (kg)\]) ÷ \[72 x serum Cr (mg/dL)\]} x 0.85~ * Hepatitis B surface antigen (HBsAg) positive~* Participation in any other study~* In labour - at onset or beyond~* Serious illness (including TB) and/or hospitalization~* Receipt of TB treatment within 30 days prior to study entry~* Fetus detected with serious congenital malformation (ultrasound not required to rule out this condition)~* History of documented structural or conduction heart defect~* Social or other circumstances which would hinder long-term follow-up, in the opinion of the site investigator~* Currently incarcerated~* Substance or alcohol abuse (a score of \>8 on the WHO Alcohol Use).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Intervention - Truvada) (Type: ACTIVE_COMPARATOR): Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
- Arm B (Control - Standard of Care) (Type: NO_INTERVENTION): Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation

Based on this trial design, predict the completion outcome and termination type (if applicable).